TIDES Europe 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

Novartis at TIDES Europe 2026

Nov 3–5, 2026 Amsterdam, Netherlands ~900 attendees Website

Novartis takes part in 2 sessions at TIDES Europe 2026 in Amsterdam. Its program centres on peptides in radioligand therapy for precision targeting in oncology. It also opens the segment on peptide process development and manufacturing.

OrganizationTIDES Europe 2026 Attendance
Novartis
Basel, Switzerland
Large pharma
Swiss pharmaceutical company whose portfolio includes the siRNA drug inclisiran and peptide-based radioligand therapies.
Chair
Wed Nov 4
13:55–14:00
Chairman's Remarks - Peptide Process Development and Manufacturing
Peptide Discovery to CMC
Talk
Wed Nov 4
11:15–11:45
Peptides in Radioligand Therapy: Precision Targeting in Oncology
How peptides carry radioactive atoms straight to cancer cells, and what that means for manufacturing and quality control.

Explore the full TIDES Europe 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Amsterdam. Leave your work email and we’ll be in touch.

Privacy

Download the full TIDES Europe 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Novartis

Tell us what you sell and we’ll find the people at Novartis most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by TIDES Europe or its organizers. Submit a correction